IDCases · 2022 · 15 citations · 9 references
MedicineInfectious DiseasesPathologyImmunology Of Infectious DiseasesImmunopathologyPulmonologyPulmonary InfectionsPulmonary InflammationPulmonary PathologyRespiratory DiseaseRespiratory InfectionsRespiratory Infectious DiseasesAnti-cd20 Antibody TherapyAnti-cd20 TherapyBronchoalveolar Lavage AnalysisBronchoalveolar Lavage ExaminationImmune InfiltratesInflammatory Lung LesionsLung Parenchymal ImagingSars-cov-2 Infection
Background: Prolonged shedding/relapse of COVID-19 infection has been reported, particularly in patients who received anti-CD20 agents (eg. rituximab). However, cases of occult COVID-19, in which SARS-CoV-2 persistence in lung parenchyma is diagnosed despite clearance from nasopharyngeal (NP) specimens, are uncommon. Case summary: We describe two cases of occult COVID-19 in immunocompromised patients. Both patients had received rituximab previously. Both cases initially presented as ground-glass infiltrates on lung imaging; the diagnosis was originally not suspected due to repeated demonstration of negative SARS-CoV-2 from NP specimens, and alternative etiologies were originally considered. Persistence of SARS-CoV-2 in lung parenchyma, however, was demonstrated on bronchoalveolar lavage (BAL) specimens; additionally, isolation of viable SARS-CoV-2 virus and detection of SARS-CoV-2 nucleocapsid and spike-protein antigen in lung tissue on immunohistochemistry close to 3-months from primary infection strongly suggested ongoing viral persistence and replication as a driver of the lung parenchymal changes, which resolved after antiviral treatment. Discussion: Occult COVID-19 can be a cause of unexplained ground-glass infiltrates on lung imaging; negative NP samples do not rule out SARS-CoV-2 persistence and invasive sampling must be considered. The unsuspected presence of viable virus on BAL, however, highlights that procedurists perfoming aerosol-generating-procedures during an ongoing pandemic wave must also practise appropriate infection-prevention precautions to limit potential exposure.
9
Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn et al. · The Lancet Rheumatology · 2021 · 211 citations · Full text
Jorge Calderón‐Parra, Elena Múñez, Ana Fernández‐Cruz et al. · Clinical Infectious Diseases · 2021 · 81 citations · Full text
Impact of rituximab on COVID-19 outcomes
Hannah Levavi, Guido Lancman, Janice Gabrilove · Annals of Hematology · 2021 · 57 citations · Full text